IGKC | OmnibusX

I. Expression across cell types

Name	Number of supported studies	Average coverage
B cell	40 studies	60% ± 17%	Explore
plasma cell	26 studies	69% ± 15%	Explore
plasmacytoid dendritic cell	24 studies	76% ± 18%	Explore
memory B cell	18 studies	55% ± 19%	Explore
naive B cell	18 studies	52% ± 20%	Explore
T cell	13 studies	39% ± 22%	Explore
mast cell	13 studies	38% ± 24%	Explore
CD8-positive, alpha-beta T cell	12 studies	38% ± 22%	Explore
fibroblast	11 studies	42% ± 20%	Explore
gamma-delta T cell	11 studies	42% ± 23%	Explore
natural killer cell	10 studies	38% ± 22%	Explore
IgG plasma cell	10 studies	74% ± 21%	Explore
macrophage	9 studies	46% ± 26%	Explore
plasmablast	9 studies	67% ± 16%	Explore
IgA plasma cell	9 studies	71% ± 23%	Explore
conventional dendritic cell	9 studies	45% ± 29%	Explore
regulatory T cell	9 studies	42% ± 22%	Explore
CD4-positive, alpha-beta T cell	8 studies	37% ± 27%	Explore
monocyte	7 studies	44% ± 27%	Explore
endothelial cell	7 studies	35% ± 18%	Explore
immature B cell	7 studies	50% ± 12%	Explore
dendritic cell	6 studies	37% ± 17%	Explore
endothelial cell of lymphatic vessel	6 studies	51% ± 19%	Explore
T follicular helper cell	6 studies	37% ± 22%	Explore
precursor B cell	6 studies	43% ± 8%	Explore
pericyte	5 studies	35% ± 20%	Explore
classical monocyte	5 studies	27% ± 11%	Explore
endothelial cell of artery	5 studies	42% ± 20%	Explore
myeloid cell	5 studies	22% ± 10%	Explore
innate lymphoid cell	5 studies	44% ± 23%	Explore
naive thymus-derived CD4-positive, alpha-beta T cell	5 studies	28% ± 7%	Explore
CD16-negative, CD56-bright natural killer cell, human	5 studies	26% ± 8%	Explore
smooth muscle cell	4 studies	40% ± 13%	Explore
goblet cell	4 studies	52% ± 21%	Explore
vein endothelial cell	4 studies	39% ± 20%	Explore
abnormal cell	4 studies	37% ± 34%	Explore
CD8-positive, alpha-beta memory T cell	4 studies	34% ± 7%	Explore
capillary endothelial cell	4 studies	39% ± 17%	Explore
mature NK T cell	4 studies	29% ± 16%	Explore
IgM plasma cell	4 studies	79% ± 17%	Explore
mucosal invariant T cell	4 studies	29% ± 16%	Explore
CD16-positive, CD56-dim natural killer cell, human	4 studies	31% ± 9%	Explore
CD4-positive helper T cell	3 studies	46% ± 9%	Explore
effector memory CD8-positive, alpha-beta T cell	3 studies	35% ± 12%	Explore
neutrophil	3 studies	39% ± 21%	Explore
germinal center B cell	3 studies	65% ± 14%	Explore
T-helper 17 cell	3 studies	55% ± 27%	Explore
erythrocyte	3 studies	30% ± 13%	Explore

II. Expression across tissues

Name	Number of supported studies	Average coverage
intestine	8 studies	41% ± 28%	Explore
peripheral blood	4 studies	30% ± 7%	Explore
lung	3 studies	41% ± 6%	Explore

Tissue	GTEx Coverage	GTEx Average TPM	GTEx Number of samples	TCGA Coverage	TCGA Average TPM	TCGA Number of samples
lung	93%	50535.31	535 / 578	83%	32366.68	954 / 1155
stomach	72%	59527.69	260 / 359	67%	16597.21	193 / 286
intestine	55%	132417.69	535 / 966	63%	12784.99	330 / 527
spleen	100%	493764.10	241 / 241	0%	0	0 / 0
breast	46%	33677.79	209 / 459	53%	12476.81	588 / 1118
esophagus	25%	9281.48	364 / 1445	56%	13853.46	102 / 183
tonsil	0%	0	0 / 0	80%	40785.71	36 / 45
peripheral blood	80%	58210.36	742 / 929	0%	0	0 / 0
bladder	29%	18700.76	6 / 21	50%	10544.81	252 / 504
uterus	24%	4652.36	41 / 170	48%	11686.11	220 / 459
liver	56%	8244.51	126 / 226	15%	3060.55	62 / 406
thymus	32%	43862.06	206 / 653	34%	13725.08	205 / 605
pancreas	10%	1477.75	32 / 328	54%	9899.61	96 / 178
kidney	39%	25092.46	35 / 89	21%	4468.46	193 / 901
ovary	22%	3367.01	39 / 180	37%	9205.76	159 / 430
lymph node	0%	0	0 / 0	59%	16036.81	17 / 29
skin	4%	512.55	67 / 1809	46%	16119.85	218 / 472
prostate	35%	11393.85	86 / 245	11%	1272.63	56 / 502
adipose	24%	8632.79	292 / 1204	0%	0	0 / 0
blood vessel	19%	6871.79	251 / 1335	0%	0	0 / 0
adrenal gland	10%	2682.35	27 / 258	7%	1036.28	16 / 230
heart	5%	1185.83	45 / 861	0%	0	0 / 0
eye	0%	0	0 / 0	5%	1971.65	4 / 80
brain	0%	51.11	10 / 2642	2%	112.51	12 / 705
muscle	1%	95.77	6 / 803	0%	0	0 / 0
abdomen	0%	0	0 / 0	0%	0	0 / 0
bone marrow	0%	0	0 / 0	0%	0	0 / 0
diaphragm	0%	0	0 / 0	0%	0	0 / 0
gingiva	0%	0	0 / 0	0%	0	0 / 0
nasal cavity	0%	0	0 / 0	0%	0	0 / 0
nasopharynx	0%	0	0 / 0	0%	0	0 / 0
nose	0%	0	0 / 0	0%	0	0 / 0
placenta	0%	0	0 / 0	0%	0	0 / 0
spinal column	0%	0	0 / 0	0%	0	0 / 0
ureter	0%	0	0 / 0	0%	0	0 / 1

III. Associated gene sets

GO_0006955	Biological process	immune response
GO_0002250	Biological process	adaptive immune response
GO_0050853	Biological process	B cell receptor signaling pathway
GO_0016064	Biological process	immunoglobulin mediated immune response
GO_0005615	Cellular component	extracellular space
GO_0071735	Cellular component	IgG immunoglobulin complex
GO_0071745	Cellular component	IgA immunoglobulin complex
GO_0072562	Cellular component	blood microparticle
GO_0070062	Cellular component	extracellular exosome
GO_0071753	Cellular component	IgM immunoglobulin complex
GO_0005576	Cellular component	extracellular region
GO_0005886	Cellular component	plasma membrane
GO_0071742	Cellular component	IgE immunoglobulin complex
GO_0071738	Cellular component	IgD immunoglobulin complex
GO_0003823	Molecular function	antigen binding

IV. Literature review

[source]

Gene name	IGKC
Protein name	Immunoglobulin kappa constant Immunoglobulin kappa constant (Ig kappa chain C region) (Ig kappa chain C region AG) (Ig kappa chain C region CUM) (Ig kappa chain C region EU) (Ig kappa chain C region OU) (Ig kappa chain C region ROY) (Ig kappa chain C region TI)
Synonyms
Description	FUNCTION: Constant region of immunoglobulin light chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . .
Accessions	ENST00000390237.2 A0A5H1ZRQ3 P01834

IGKC report

I. Expression across cell types

II. Expression across tissues

III. Associated gene sets

IV. Literature review